Primary Biliary Cirrhosis Clinical Trial
Official title:
Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis, a Randomized Double-blind Placebo Controlled Trial
Ursodeoxycholic acid is the mainstay treatment medicine for primary biliary cholangitis(PBC). About 1/3 of the patients do not respond to UDCA, which is defined as refractory PBC. Mesenchymal stem cells (MSC) has been reported to improve the outcomes of PBC patients. Randomization controlled studies are needed to confirm the long term effect of MSC treatment for refractory PBC. This study aimed to investigate the safety and efficacy of mesenchymal stem cells in PBC patients that do not respond to UDCA treatment. This study is an double-blind multicenter randomized and placebo-controlled study. Patients with with refractory PBC will be randomly assigned to receive MSC treatment plus UDCA or UDCA alone (control). Three times of MSC infusion (0.1-1x10E6 cells/kg body weight) via peripheral vein will be given to the experimental group (once in 4 weeks). The primary outcome is absolute change in alkaline phosphatase. Secondary outcomes are changes of other liver function indices such as ALT TBIL AST GGT, improve of symptoms and liver histology.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04526665 -
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
|
Phase 3 | |
| Recruiting |
NCT02931513 -
sCD163 in PBC Patients - Assessment of Treatment Response
|
||
| Active, not recruiting |
NCT02924701 -
sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis
|
||
| Completed |
NCT02659696 -
Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis
|
||
| Completed |
NCT02078882 -
Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis
|
Phase 4 | |
| Completed |
NCT01389973 -
A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid
|
Phase 2 | |
| Completed |
NCT01603199 -
High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis
|
N/A | |
| Completed |
NCT01857284 -
Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis
|
Phase 3 | |
| Completed |
NCT05374200 -
Mind-body Wellness Intervention in Primary Biliary Cholangitis (PBC)
|
N/A | |
| Recruiting |
NCT02937012 -
Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders
|
Phase 3 | |
| Completed |
NCT02376335 -
B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis
|
Phase 2 | |
| Recruiting |
NCT01662973 -
Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04751188 -
A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis
|
Phase 3 | |
| Recruiting |
NCT04514965 -
Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)
|
||
| Completed |
NCT02955602 -
Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)
|
Phase 2 | |
| Completed |
NCT02557360 -
Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis
|
Phase 4 | |
| Recruiting |
NCT01440309 -
Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis
|
Phase 1 | |
| Completed |
NCT01249092 -
Pentoxifylline for Primary Biliary Cirrhosis
|
Phase 2 | |
| Completed |
NCT01510860 -
Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis
|
Phase 4 | |
| Completed |
NCT04604652 -
Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
|
Phase 2 |